A Polypill for Acute Coronary Syndrome
This study is looking at whether combining standard medications into one "polypill" can help people who have recently had acute coronary syndrome (ACS), which includes heart attacks. The polypill will contain aspirin, a P2Y12 inhibitor (like prasugrel or clopidogrel), and a high-intensity statin. Researchers want to see if taking these medicines together in one pill improves health outcomes over 6 months compared to taking them separately. You might be able to join if you are at least 18 years old, were hospitalized for ACS, had a procedure called percutaneous coronary intervention, and are currently taking aspirin, prasugrel or clopidogrel, and a high-intensity statin. The study is aiming to include 1000 participants.
- Study design
- This is a multi-center, randomized study, meaning participants will be randomly assigned to receive either the polypill or standard separate medications. The study plans to enroll 1000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main results will be measured at 6 months after starting the treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Polypill for Acute Coronary Syndrome
At a glance
Conditions
NCT07032389
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Baylor Scott and White Health System
Dallas, Texasstudy coordinator listed
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Win ratio6-months
The win ratio will include all-cause death, in-stent thrombosis, ischemic events (MI, hospitalization for unstable angina, unplanned revascularization), and bleeding events (hospitalization or ED visit for bleeding, red blood cell transfusion, or a bleeding event that leads to cessation of DAPT)